Follow us 

© 2013 Ventana Medical Systems, Inc.   Terms and conditions | Privacy Policy  

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

VENTANA and the VENTANA logo are trademarks of Roche.

All other trademarks are the property of their respective owners.

See BRAF differently, now with IHC
Introducing the new BRAF V600E (VE1)
antibody, only from Ventana

Empowering | Innovation
To get a free copy of the whitepaper, “Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-
BRAF V600E (VE1) Antibody: A Comparison with Sanger Sequencing” please submit your information below
Fast, accurate results can make the difference in diagnostic decisions. Improve your
immunohistochemistry laboratory workflow with the only ready-to-use BRAF V600E
IVD antibody on the market: the VENTANA BRAF V600E (VE1) Mouse Monoclonal
Primary Antibody.

Optimize your lab's IHC performance with the BRAF V600E (VE1) antibody

  • Use one test to evaluate a variety of cancers
  • High sensitivity and specificity
  • High concordance with existing molecular techniques
  • Allows high quality staining with morphological context
When used with VENTANA BenchMark IHC/ISH staining platforms and OptiView DAB
IHC detection, the VENTANA BRAF V600E (VE1) assay is a powerful tool to detect the
BRAF V600E mutation. BRAF V600E is a clinically significant mutation in a variety
of cancers, including colorectal, papillary thyroid and hairy cell leukemia.

Empower your laboratory to test for these and other cancers quickly, easily and
accurately with the VENTANA BRAF V600E (VE1) Mouse Monoclonal Primary

“The BRAF V600E mutation is particularly important because it is both the
most common mutation that is seen… and functionally, it is the most
important mutation.”

— Dr. Jayesh Desai, University of Melbourne
Colorectal carcinoma positive for BRAF V600E (VE1) IHC with OptiView DAB IHC detection
Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with
anti-BRAF V600E (VE1) Antibody: A Comparison with Sanger Sequencing